|
| Friday, 18 December 2020, 11:00 HKT/SGT | |
| |  | |
Source: ZENUM Sarl | |
|
|
|
|
| Identify from a drop of blood whether a person's Covid-19 vaccine is still valid, in 5 Minutes! |
Epalinges, Switzerland, Dec 18, 2020 - (ACN Newswire) - Swiss high-tech company ZENUM has developed one of the most advanced technologies in the fight against Covid-19, and it could be ready for distribution as early as next month. The world's first five-minute portable Coronavirus test will also detect how much immunity remains after taking a vaccine.
 | | NANOFLUIDIC RAPID TEST KIT - Identify from a drop of blood whether a person's Covid-19 vaccine is still valid - in 5 Minutes!
ZENUM SWITZERLAND 2021 |
The game-changing ZEKNANO rapid test kit uses a tiny finger-prick blood sample, instead of swabs. It can be taken anywhere, has close to 100% accuracy, and also measures severity of infection. Thanks to nanotechnology, ZEKNANO not only detects Covid-19 within five minutes, but it identifies up to 14 different conditions simultaneously, including flu virus and infectious diseases.
Artificial Intelligence (AI) is at the heart of the revolutionary product. A neural network - a series of algorithms designed to function like a human brain - has been added to increase the test's efficiency, and study any mutation of the virus.
As the device is portable and lightweight, the tests do not have to be administered only in medical settings. This makes it a leading contender to tackle coronavirus and other diseases in the developing world. It also has the potential to help control the pandemic across all countries before another possible surge in the coming months.
ZENUM already produces 15-minute coronavirus rapid test kits for antibodies and antigens, under the brand ZEKMED. The performance evaluation of these kits were conducted by CIRION Biopharma, one of the few CLIA laboratories in Canada. The results are in accordance with three independent evaluations conducted in Russia, Switzerland and France.
The new ZEKNANO five-minute test is expected to be certified for use in January, putting it ahead of several ongoing projects to achieve such rapid results.
Emidio Do Sacramento, founder and CEO of ZENUM, said: "It doesn't matter if it's a 5 or 15 minute rapid test. Our focus is to help practitioners and health institutions, the best we can, to save lives.
"The reality is that the world is in need of products that solve a problem, and not a marketing sales campaign promoting companies or universities, whether that product is from our company or any other.
"Enough is enough. Mass testing, fast and accurate patient triage is the only reliable solution before any vaccine reaches enough people. We need our lives and economy back to 'normal'."
About ZENUM
ZENUM's origins are rooted in a collaborative network of innovators who strive in the development of applications/mediums/security using biometrics, Ai and blockchain technologies and the infinite influences these technologies will have on life.
As a result of our developments in these fields with our project collaborators and likeminded partners, we found ourselves already engaged and working in the field of medical pre-diagnosis using biometric data for example the research into the pre-diagnosis of glaucoma.
ZENUM is located in new facilities at BIOPOLE, the Life Sciences Campus - one of the largest healthcare research campuses in Europe, and has important medical partnerships in Switzerland, Germany and China. Full technical details can be found at https://zekmed.com/zeknano.html
For more information, please contact:
Emidio Do Sacramento, CEO, Zenum
E: es@zenum.swiss, es@zekmed.com, https://zekmed.com
About the CEO:
https://tinyurl.com/Forbes-Sacramento
https://www.linkedin.com/in/emidiosacramento/
https://www.linkedin.com/company/zenum-technologies/
Topic: Press release summary
Source: ZENUM Sarl
Sectors: Healthcare & Pharm, MedTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
Everest Medicines Announces NMPA Acceptance of the BLA for LEROCHOL(R), Offering a Potential New Treatment Option for Hypercholesterolemia in China
June 26, 2026 22:26 HKT/SGT
|
|
|
PT Merdeka Gold Resources Tbk Debuts on the Main Board of HKEX with a Secondary Listing 
June 26, 2026 22:20 HKT/SGT
|
|
|
Tong Ren Tang Healthcare (02667.HK), Targets Hong Kong IPO
June 26, 2026 21:16 HKT/SGT
|
|
|
IP Go-Global Business Matching Session held in Guangzhou
June 26, 2026 19:36 HKT/SGT
|
|
|
JCB and PNB Launch New Platinum Credit Card, Empowering Consumers with Greater Value and Lifestyle Benefits
Friday, June 26, 2026 5:00:00 PM
|
|
|
KEYTOP PARKING INC. Officially Lists on the Main Board of Hong Kong Stock Exchange
June 26, 2026 10:55 HKT/SGT
|
|
|
XJTLU Strengthens Presence in Indonesia, Offers Double Degrees and Global Career Pathways
June 26, 2026 10:00 HKT/SGT
|
|
|
CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World's First Bispecific Antibody for Passive Immunization Against Rabies
June 26, 2026 09:00 HKT/SGT
|
|
|
GIC Discloses Third Change in Shareholding in Ascletis Pharma Inc. -B (01672.HK) This Year: Further Increases Stake by Over 10 Million Shares, Raising Holding from 7.00% to 8.36%
June 26, 2026 08:37 HKT/SGT
|
|
|
GA-ASI Adapts Ground Control Station to Fly MQ-9B
June 25, 2026 22:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
 |
|
 |
|
